Skip to main content
OpenTrials
Completed

NCT Number: NCT00829114

Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)

Non-randomized, comparative study (1:1 allocation) to study interactions between nevirapine-containing antiretroviral therapies and combined oral contraceptive pills.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

, RHRU National Office, University of Witwatersand, Esselent Saint Hillbrow, Johannesburg, South Africa

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to provide informed consent
  • Willing to take COCs and follow all study requirements
  • Has regular menstrual cycles every 21-35 days (when not taking hormonal contraception)
  • Last menstrual period (LMP) <35 days before study entry
  • Has body mass index of 18-30
  • Negative urine pregnancy test as enrollment
  • Documented HIV-1 infection
  • On nevirapine-containing ART for at least three months (ART group only)
  • CD4 cell count of greater than or equal to 350 (for non-ARV group only)
  • Currently sexually active and plans to stay sexually active for the next 6 months

Exclusion criteria

  • Medical contraindications to COC use
  • Recent pregnancy (within 3 months)
  • Has breastfed in last 3 months
  • Last pregnancy was ectpoic
  • Has been sterilized
  • Has had any of the following conditions since last pregnancy, or since menarche if never pregnant:

Pelvic Inflammatory disease Diagnosis of infertility

  • Has had DMPA within 6 months or NET injectable within 3 months of study entry (or has had no menses since last injection regardless of its timing)
  • has taken other hormonal therapies besides COCs (e.g., combined injectables, progestin implants or intrauterine systems, progestin-only contraceptive pills, medroxyprogesterone acetate, hormone replacement therapy) within 30 days of study entry
  • Has an acute infection or other opportunistic diseases requiring therapy within 14 days before enrollment
  • Has active drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements
  • Has taken any prohibited medication within 30 days before study entry
  • Has chronic diarrhea, malabsorption or inability to maintain an adequate oral intake
  • Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe or complicate data interpretation

Treatment and study plan

ETHINYL ESTRADIOL AND LEVOGESTREL

Drug

30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL

Primary outcomes

  1. Ovulation as determined by weekly blood progesterone (P) measurement

    Time frame: 2 months

Secondary outcomes

  1. Pregnancy as detected by monthly urine pregnancy testing

    Time frame: 6 months

  2. Adverse events (AE) recording

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

FHI 360

Other

Collaborators

  • Makerere University
  • RHRU National Office, University of Witwatersand, Johannesburg
  • United States Agency for International Development (USAID)

Registry information

Official study title

Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Jan 26, 2009
Registry last updated
Oct 31, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.